- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$81.15

Market cap

$205.31B

P/E Ratio

17.84

Dividend/share

$2.48

EPS

$4.55

Enterprise value

$226.7B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

The P/E is 57% lower than the 5-year quarterly average of 41.6 and 11% lower than the last 4 quarters average of 20.0

The EPS has grown by 26% YoY and by 10% from the previous quarter

MRK's debt is up by 10% year-on-year but it is down by 7% since the previous quarter

MRK's quick ratio is down by 8% since the previous quarter and by 3.8% year-on-year

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.53B

Market cap

$205.31B

Enterprise value

$226.7B

Price to earnings (P/E)

17.84

Price to book (P/B)

7.03

Price to sales (P/S)

4.33

EV/EBIT

16.72

EV/EBITDA

13.17

EV/Sales

4.79

Revenue

$47.35B

EBIT

$13.56B

EBITDA

$17.21B

Free cash flow

$6.73B

Per share
Balance sheet
Liquidity

EPS

$4.55

Free cash flow per share

$2.66

Book value per share

$11.54

Revenue per share

$18.72

TBVPS

$20.91

Total assets

$89.8B

Total liabilities

$60.53B

Debt

$28.74B

Equity

$29.19B

Working capital

$6.17B

Debt to equity

0.98

Current ratio

1.3

Quick ratio

0.77

Net debt/EBITDA

1.24

Margins
Efficiency
Dividend

EBITDA margin

36.4%

Gross margin

71.2%

Net margin

24.3%

Operating margin

26.9%

Return on assets

13.2%

Return on equity

42.3%

Return on invested capital

27.6%

Return on capital employed

19.5%

Return on sales

28.6%

Dividend yield

3.06%

DPS

$2.48

Payout ratio

54.5%

How has the Merck stock price performed over time

Intraday

0.21%

1 week

-2.67%

1 month

1.26%

1 year

-5.62%

YTD

-0.79%

QTD

-0.79%

How have Merck's revenue and profit performed over time

Revenue

$47.35B

Gross profit

$33.73B

Operating income

$12.72B

Net income

$11.52B

Gross margin

71.2%

Net margin

24.3%

The net income is up by 24% year-on-year and by 10% since the previous quarter

MRK's net margin is up by 20% year-on-year and by 9% since the previous quarter

Merck's operating income has increased by 8% YoY and by 6% from the previous quarter

Merck's operating margin has increased by 6% QoQ and by 5% YoY

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

17.84

P/B

7.03

P/S

4.33

EV/EBIT

16.72

EV/EBITDA

13.17

EV/Sales

4.79

The P/E is 57% lower than the 5-year quarterly average of 41.6 and 11% lower than the last 4 quarters average of 20.0

The EPS has grown by 26% YoY and by 10% from the previous quarter

The price to book (P/B) is 21% higher than the 5-year quarterly average of 5.8 but 9% lower than the last 4 quarters average of 7.7

Merck's equity has increased by 9% YoY and by 6% from the previous quarter

The revenue has grown by 3% YoY

How efficient is Merck business performance

Merck's ROE has increased by 23% YoY and by 8% from the previous quarter

The ROIC rose by 21% YoY and by 6% QoQ

The company's return on assets rose by 18% YoY and by 8% QoQ

The ROS has grown by 15% YoY and by 8% from the previous quarter

What is MRK's dividend history

DPS

$2.48

Dividend yield

3.06%

Payout ratio

54.5%

Recent dividends

How did Merck financials performed over time

The total assets is 48% more than the total liabilities

MRK's quick ratio is down by 8% since the previous quarter and by 3.8% year-on-year

Merck's total liabilities has increased by 7% YoY but it has decreased by 3.7% QoQ

MRK's debt is up by 10% year-on-year but it is down by 7% since the previous quarter

Merck's equity has increased by 9% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.